By Jame Abraham, MD, FACP, and Brian J. Bolwell, MD, FACPDecember 25, 2019 Dr. Smith called us on a Tuesday afternoon. “I have a patient who has an abnormal mammogram showing a large mass. I’m suspecting cancer and am referring her to you for diagnosis and treatment. She’s very anxious. I hope you can help.” …
More than 650 clinicians, advanced practice providers, nurses, administrators, trainees and other healthcare professionals participated Content is property of Cleveland Clinic and for news media…
Jame Abraham: Our Inaugural Artificial Intelligence Conference / Albert Marinez, Artificial Intelligence Conference, Ben Shahshahani, Bethany Frampton,
In 1986, approximately three decades after the discovery of estrogen and progesterone receptors, the human epidermal growth factor receptor 2 (HER2) oncogene was linked to…
This year, more than 2 million people in the United States are expected to be diagnosed with some form of cancer, according to the American Cancer…
This year, more than 2 million people in the United States are expected to be diagnosed with some form of cancer, according to the American Cancer…
Christopher Weight, MD, Director of Urologic Oncology at Cleveland Clinic joins the Cancer Advances podcast to discuss using artificial intelligence to predict prostate cancer outcomes…
Christopher Weight, MD, Director of Urologic Oncology at Cleveland Clinic joins the Cancer Advances podcast to discuss using artificial intelligence to predict prostate cancer outcomes…
In this installment of The ASCO Post’s Living a Full Life series, Stephen R. Grobmyer, MD, FACS, speaks about his clinical and research career in…
Register for Cleveland Clinic’s 8th Annual Cleveland Breast Cancer Summit: Collaborating for a Cure, Friday August 9, 2024 LIVE at the Intercontinental Hotel & Conference…
Taletrectinib, an experimental oral next-generation tyrosine kinase inhibitor (TKI), has demonstrated robust clinical activity in the treatment of ROS1-positive non-small cell lung cancer (NSCLC).
